Possible high risk of thrombotic events in patients with paroxysmal nocturnal haemoglobinuria after discontinuation of eculizumab

British Journal of Haematology

Volumn 157, Issue 6, 2012, Pages 762-763

  van Bijnen, Sandra T A ^a   van Rijn, Roos S ^b   Koljenovic, Senada ^b   te Boekhorst, Peter ^b   de Witte, Theo ^a   Muus, Petra ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Eculizumab; Paroxysmal nocturnal haemoglobinuria; Thrombosis

Indexed keywords

ANTICOAGULANT AGENT; ECULIZUMAB; LACTATE DEHYDROGENASE; PHENPROCOUMON;

ABDOMINAL PAIN; ABDOMINAL SURGERY; ADULT; APLASTIC ANEMIA; BONE MARROW BIOPSY; CASE REPORT; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG SAFETY; DRUG WITHDRAWAL; DUODENUM ULCER; ENDOSCOPY; ERYTHROCYTE TRANSFUSION; FEMALE; HEMATEMESIS; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LETTER; OUTCOME ASSESSMENT; PANCYTOPENIA; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PRIORITY JOURNAL; QUALITY OF LIFE; RISK ASSESSMENT; RISK FACTOR; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; VEIN THROMBOSIS; VOMITING;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; HEMOGLOBINURIA, PAROXYSMAL; HUMANS; RISK FACTORS; THROMBOSIS;

EID: 84861529293     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2012.09073.x     Document Type: Letter

References (9)

1. van Bijnen, S.T., van Heerde, W.L. & Muus, P. (2011) Mechanisms and Clinical Implications of Thrombosis in Paroxysmal Nocturnal Hemoglobinuria. Journal of Thrombosis and Haemostasis, DOI: 10.1111/j.1538-7836.2011.04562.x.
2. Grunewald, M., Grunewald, A., Schmid, A., Schopflin, C., Schauer, S., Griesshammer, M. & Koksch, M. (2004) The platelet function defect of paroxysmal nocturnal haemoglobinuria. Platelets, 15, 145-154.
3. Hall, C., Richards, S. & Hillmen, P. (2003) Primary prophylaxis with warfarin prevents thrombosis in paroxysmal nocturnal hemoglobinuria (PNH). Blood, 102, 3587-3591.
4. Hillmen, P., Young, N.S., Schubert, J., Brodsky, R.A., Socie, G., Muus, P., Roth, A., Szer, J., Elebute, M.O., Nakamura, R., Browne, P., Risitano, A.M., Hill, A., Schrezenmeier, H., Fu, C.L., Maciejewski, J., Rollins, S.A., Mojcik, C.F., Rother, R.P. & Luzzatto, L. (2006) The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. New England Journal of Medicine, 355, 1233-1243.
5. Hillmen, P., Muus, P., Duhrsen, U., Risitano, A.M., Schubert, J., Luzzatto, L., Schrezenmeier, H., Szer, J., Brodsky, R.A., Hill, A., Socie, G., Bessler, M., Rollins, S.A., Bell, L., Rother, R.P. & Young, N.S. (2007) Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood, 110, 4123-4128.
6. de Latour, R.P., Mary, J.Y., Salanoubat, C., Terriou, L., Etienne, G., Mohty, M., Roth, S., de, G.S., Maury, S., Cahn, J.Y. & Socie, G. (2008) Paroxysmal nocturnal hemoglobinuria: natural history of disease subcategories. Blood, 112, 3099-3106.
7. Rother, R.P., Bell, L., Hillmen, P. & Gladwin, M.T. (2005) The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease. JAMA, 293, 1653-1662.
8. Schubert, J., Hillmen, P., Roth, A., Young, N.S., Elebute, M.O., Szer, J., Gianfaldoni, G., Socie, G., Browne, P., Geller, R., Rother, R.P. & Muus, P. (2008) Eculizumab, a terminal complement inhibitor, improves anaemia in patients with paroxysmal nocturnal haemoglobinuria. British Journal of Haematology, 142, 263-272.
9. Volanakis, J.E. (1995) Transcriptional regulation of complement genes. Annual Review of Immunology, 13, 277-305.